Published in Science on December 16, 2004
Inflammation and insulin resistance. J Clin Invest (2006) 18.76
Inflammation, stress, and diabetes. J Clin Invest (2005) 17.11
Adipocytes as regulators of energy balance and glucose homeostasis. Nature (2006) 9.52
Adipokines in inflammation and metabolic disease. Nat Rev Immunol (2011) 8.92
Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol (2010) 8.55
Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell (2007) 6.47
Misconduct accounts for the majority of retracted scientific publications. Proc Natl Acad Sci U S A (2012) 5.89
The metabolic syndrome. Endocr Rev (2008) 5.33
Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab (2007) 4.16
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev (2009) 3.23
Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab (2008) 3.11
Adipokines and insulin resistance. Mol Med (2008) 2.97
Intracellular signalling pathways activated by leptin. Biochem J (2006) 2.93
Inflammatory mechanisms in the regulation of insulin resistance. Mol Med (2008) 2.71
Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab (2008) 2.47
TNF-alpha and adipocyte biology. FEBS Lett (2007) 2.37
Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci (2008) 2.26
Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.25
Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci (2014) 2.03
Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm (2010) 1.80
Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res (2009) 1.74
Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des (2009) 1.69
Metabolic preconditioning of donor organs: defatting fatty livers by normothermic perfusion ex vivo. Metab Eng (2009) 1.66
Non-invasive means of measuring hepatic fat content. World J Gastroenterol (2008) 1.60
The NAD World: a new systemic regulatory network for metabolism and aging--Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem Biophys (2009) 1.58
Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp Gerontol (2006) 1.49
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One (2008) 1.48
Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum (2009) 1.45
Potential markers of preeclampsia--a review. Reprod Biol Endocrinol (2009) 1.44
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab (2006) 1.42
SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim Biophys Acta (2009) 1.41
Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury. Am J Respir Crit Care Med (2008) 1.38
Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med (2005) 1.37
Adipocyte, adipose tissue, and infectious disease. Infect Immun (2006) 1.36
Skeletal muscle NAMPT is induced by exercise in humans. Am J Physiol Endocrinol Metab (2009) 1.36
Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia (2011) 1.32
Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem (2008) 1.29
Adaptation and maladaptation of the heart in obesity. Hypertension (2008) 1.29
Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm (2009) 1.26
Medicine. Visfatin: a new adipokine. Science (2004) 1.26
Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr (2008) 1.25
Vascular biology of metabolic syndrome. J Vasc Surg (2011) 1.21
The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med (2008) 1.21
Inflammation and Nutritional Science for Programs/Policies and Interpretation of Research Evidence (INSPIRE). J Nutr (2015) 1.20
Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia (2008) 1.19
Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res (2013) 1.19
Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol (2013) 1.17
Molecular processes during fat cell development revealed by gene expression profiling and functional annotation. Genome Biol (2005) 1.16
Sirtuins and their relevance to the kidney. J Am Soc Nephrol (2010) 1.15
Fat: a matter of disturbance for the immune system. World J Gastroenterol (2010) 1.13
Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. Front Biosci (Landmark Ed) (2009) 1.12
Obesity, inflammation and diet. Pediatr Gastroenterol Hepatol Nutr (2013) 1.11
Is PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome? Curr Hypertens Rep (2007) 1.08
Hormonal activity of AIMP1/p43 for glucose homeostasis. Proc Natl Acad Sci U S A (2006) 1.08
Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol (2015) 1.06
Egr-1 decreases adipocyte insulin sensitivity by tilting PI3K/Akt and MAPK signal balance in mice. EMBO J (2011) 1.05
Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev (2012) 1.05
Quantitative trait loci for individual adipose depot weights in C57BL/6ByJ x 129P3/J F2 mice. Mamm Genome (2006) 1.05
Adipokines - removing road blocks to obesity and diabetes therapy. Mol Metab (2014) 1.04
Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal (2012) 1.04
Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm (2013) 1.03
Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis. Rheumatol Int (2011) 1.02
Membrane raft-lysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin. Cardiovasc Res (2010) 1.01
Nicotinamide Phosphoribosyltransferase in Human Diseases. J Bioanal Biomed (2011) 1.01
Targeted, LCMS-based Metabolomics for Quantitative Measurement of NAD(+) Metabolites. Comput Struct Biotechnol J (2013) 1.01
Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. Arthritis Res Ther (2014) 1.00
The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br J Pharmacol (2012) 1.00
Cytokines in the Progression of Pancreatic β-Cell Dysfunction. Int J Endocrinol (2010) 0.99
Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci (2008) 0.99
Adipokines and osteoarthritis: novel molecules involved in the pathogenesis and progression of disease. Arthritis (2011) 0.98
Adipokines: Biomarkers for osteoarthritis? World J Orthop (2014) 0.98
Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS One (2011) 0.97
Nicotinamide phosphoribosyltransferase in malignancy: a review. Genes Cancer (2013) 0.97
Resveratrol and red wine, healthy heart and longevity. Heart Fail Rev (2010) 0.96
Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis. Mol Med (2011) 0.95
Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b in colorectal cancer cells. PLoS One (2013) 0.95
Adipokines, metabolic syndrome and rheumatic diseases. J Immunol Res (2014) 0.95
Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases. Mediators Inflamm (2012) 0.95
Etiopathogenesis of nonalcoholic steatohepatitis: role of obesity, insulin resistance and mechanisms of hepatotoxicity. Int J Hepatol (2012) 0.95
Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health. Front Endocrinol (Lausanne) (2013) 0.94
Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling. Am J Physiol Heart Circ Physiol (2012) 0.94
Metabolic effects of obesity: A review. World J Diabetes (2010) 0.94
Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochim Biophys Acta (2010) 0.94
Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns. Arch Med Sci (2015) 0.93
Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure. J Card Fail (2011) 0.93
Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer. World J Gastroenterol (2014) 0.93
Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation (2013) 0.93
Visfatin in human pregnancy: maternal gestational diabetes vis-à-vis neonatal birthweight. J Perinat Med (2009) 0.92
From heterochromatin islands to the NAD World: a hierarchical view of aging through the functions of mammalian Sirt1 and systemic NAD biosynthesis. Biochim Biophys Acta (2009) 0.92
Insulin suppresses endotoxin-induced oxidative, nitrosative, and inflammatory stress in humans. Diabetes Care (2010) 0.92
SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates Hypothalamic NAD+ and Function in Mice. Cell Metab (2015) 0.92
Endothelial NLRP3 inflammasome activation and enhanced neointima formation in mice by adipokine visfatin. Am J Pathol (2014) 0.92
Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS One (2014) 0.91
The effect of omega-3 on the serum visfatin concentration in patients with type II diabetes. J Res Med Sci (2011) 0.91
Effects of bariatric surgery on adipokine-induced inflammation and insulin resistance. Front Endocrinol (Lausanne) (2013) 0.90
Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators Inflamm (2010) 0.90
Is all fat the same? The role of fat in the pathogenesis of the metabolic syndrome and type 2 diabetes mellitus. Surgery (2006) 0.90
Inflammatory markers and bariatric surgery: a meta-analysis. Inflamm Res (2012) 0.90
Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions. Cytokine Growth Factor Rev (2013) 0.90
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Generation of germline-competent induced pluripotent stem cells. Nature (2007) 32.77
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol (2007) 21.93
The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell (2003) 17.72
Generation of mouse induced pluripotent stem cells without viral vectors. Science (2008) 15.25
Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest (2004) 13.42
Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science (2008) 10.55
Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature (2009) 9.75
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet (2007) 9.56
Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med (2002) 8.95
Suppression of aging in mice by the hormone Klotho. Science (2005) 8.11
Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem (2010) 8.09
A more efficient method to generate integration-free human iPS cells. Nat Methods (2011) 7.39
Nanog is the gateway to the pluripotent ground state. Cell (2009) 7.27
Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc (2007) 7.01
Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes (2007) 6.81
Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol (2009) 6.39
Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med (2005) 6.04
Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol (2003) 4.86
Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem (2003) 4.38
Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell (2009) 4.38
Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol (2005) 4.20
Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med (2004) 4.05
Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol (2011) 3.97
Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol (2003) 3.89
Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem (2003) 3.86
Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation (2002) 3.81
Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol (2003) 3.78
Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation (2003) 3.73
mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol (2004) 3.72
Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet (2002) 3.68
Reactivation of the paternal X chromosome in early mouse embryos. Science (2004) 3.59
Autophagy is essential for preimplantation development of mouse embryos. Science (2008) 3.55
Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab (2006) 3.34
Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes (2003) 3.28
FSP27 contributes to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. J Clin Invest (2008) 3.25
Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res (2004) 3.16
Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation (2008) 3.11
Role of ERas in promoting tumour-like properties in mouse embryonic stem cells. Nature (2003) 3.08
Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem (2002) 3.05
Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell (2009) 3.03
Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem (2004) 3.01
Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A (2004) 2.85
Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med (2012) 2.80
The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb (2005) 2.77
Generation of retinal cells from mouse and human induced pluripotent stem cells. Neurosci Lett (2009) 2.75
Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res (2007) 2.66
Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension (2004) 2.65